A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.
A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.
Recruiting · NCT07356453 · Registry updated 2026-09-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors. | Advanced Solid Tumors | Recruiting | Phase 1 | 2026-09-10 | NCT07356453 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| FoRx Therapeutics AG | 1 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Knight Cancer Institute | Portland | United States | 1 |
| NEXT - Virginia Cancer Specialists | Fairfax | United States | 1 |
| Stanford University Medical Center | Palo Alto | United States | 28 |
| START - Midwest | Grand Rapids | United States | 5 |
| START - San Antonio | San Antonio | United States | 7 |
| University of California, San Francisco | San Francisco | United States | 294 |
| University of Texas - MD Anderson Cancer Center | Houston | United States | 8 |
| Washington University St. Louis | St Louis | United States | 1 |